Mural Oncology Gears Up for Key Data Readouts of Nemvaleukin in Ovarian Cancer and Melanoma in 2025
• Mural Oncology's ARTISTRY-7 trial evaluating nemvaleukin with pembrolizumab in platinum-resistant ovarian cancer has reached 75% of overall survival events.
• Top-line data from ARTISTRY-6, a phase 2 trial of nemvaleukin monotherapy in mucosal melanoma, is expected in Q2 2025, potentially supporting accelerated approval.
• Preliminary data for less-frequent intravenous dosing of nemvaleukin in cutaneous melanoma is anticipated in 1H and 2H 2025 for monotherapy and combination therapy, respectively.
• Mural Oncology plans to submit an IND application for MURA-8518, a novel IL-18 candidate, in Q4 2025, expanding its cytokine-based immunotherapy pipeline.
© Copyright 2025. All Rights Reserved by MedPath